An update on adjuvant systemic therapy for elderly patients with early breast cancer

References

• DeSantis CE, Fedewa SA, Goding Sauer A, et al. Breast cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J Clin. 2016;66(1):31–42.
   PubMed Web of Science ®Google Scholar
• Christman K, Muss HB, Case LD, et al. Chemotherapy of metastatic breast cancer in the elderly. Piedmont Oncol Assoc Exper JAMA. 1992;268(1):57–62.
   Google Scholar
• National Comprehensive Cancer Network. Older adult oncology (Version 1.2016). Available from: http://www.nccn.org/professionals/physician_gls/pdf/senior.pdf
   Google Scholar
• Extermann M, Aapro M, Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005;55(3):241–252.
   PubMed Web of Science ®Google Scholar
• Decoster L, Van Puyvelde K, Mohile S, et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations. Ann Oncol. 2015;26(2):288–300.
   PubMed Web of Science ®Google Scholar
• Pallis AG, Fortpied C, Wedding U, et al. EORTC elderly task force position paper: approach to the older cancer patient. Eur J Cancer. 2010;46(9):1502–1513.
   PubMed Web of Science ®Google Scholar
• Stuck AE, Siu AL, Wieland GD, et al. Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet. 1993;342(8878):1032–1036.
   PubMed Web of Science ®Google Scholar
• Extermann M, Meyer J, McGinnis M, et al. A comprehensive geriatric intervention detects multiple problems in older breast cancer patients. Crit Rev Oncol Hematol. 2004;49(1):69–75.
   PubMed Web of Science ®Google Scholar
• Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist. 2000;5(3):224–237.
   PubMedGoogle Scholar
• Soubeyran P, Fonck M, Blanc-Bisson C, et al. Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol. 2012;30(15):1829–1834.
   PubMed Web of Science ®Google Scholar
• Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol. 2007;25(14):1824–1831.
   PubMed Web of Science ®Google Scholar
• Puts MT, Santos B, Hardt J, et al. An update on a systematic review of the use of geriatric assessment for older adults in oncology. Ann Oncol. 2014;25(2):307–315.
   PubMed Web of Science ®Google Scholar
• Yee KW, Pater JL, Pho L, et al. Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? J Clin Oncol. 2003;21(8):1618–1623.
   PubMed Web of Science ®Google Scholar
• Muss HB, Woolf S, Berry D, et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA. 2005;293(9):1073–1081.
   PubMed Web of Science ®Google Scholar
• Jones S, Holmes FA, O’Shaughnessy J, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of us oncology research trial 9735. J Clin Oncol. 2009;27(8):1177–1183.
   PubMed Web of Science ®Google Scholar
• Muss HB, Berry DA, Cirrincione CT, et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009;360(20):2055–2065.
   PubMed Web of Science ®Google Scholar
• Denduluri N, Somerfield MR, Eisen A, et al. Selection of optimal adjuvant chemotherapy regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -negative and adjuvant targeted therapy for HER2-positive breast cancers: an American Society of Clinical Oncology guideline adaptation of the cancer care Ontario clinical practice guideline. J Clin Oncol. 2016. pii: JCO670182. [Epub ahead of print]
   Web of Science ®Google Scholar
• von Minckwitz G, Conrad B, Reimer T, et al. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52). Cancer. 2015;121(20):3639–3648.
   PubMed Web of Science ®Google Scholar
• Hoppe S, Rainfray M, Fonck M, et al. Functional decline in older patients with cancer receiving first-line chemotherapy. J Clin Oncol. 2013;31(31):3877–3882.
   PubMed Web of Science ®Google Scholar
• Sehl M, Lu X, Silliman R, et al. Decline in physical functioning in first 2 years after breast cancer diagnosis predicts 10-year survival in older women. J Cancer Surviv. 2013;7(1):20–31.
   PubMed Web of Science ®Google Scholar
• Yellen SB, Cella DF, Leslie WT. Age and clinical decision making in oncology patients. J Natl Cancer Inst. 1994;86(23):1766–1770.
   PubMedGoogle Scholar
• Craig BM, Reeve BB, Cella D, et al. Demographic differences in health preferences in the United States. Med Care. 2014;52(4):307–313.
   PubMed Web of Science ®Google Scholar
• Fried TR, Bradley EH, Towle VR, et al. Understanding the treatment preferences of seriously ill patients. N Engl J Med. 2002;346(14):1061–1066.
   PubMed Web of Science ®Google Scholar
• Elinder C-G, Bárány P, Heimbürger O. The use of estimated glomerular filtration rate for dose adjustment of medications in the elderly. Drugs Aging. 2014;31(7):493–499.
   PubMed Web of Science ®Google Scholar
• Crivellari D. Results of adjuvant treatments in breast cancer patients over 70 years old: the IBCSG experience. International Breast Cancer Study Group. Tumori. 2002;88(Suppl 1):S81–82.
   Google Scholar
• Dees EC, O’Reilly S, Goodman SN, et al. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest. 2000;18(6):521–529.
   PubMed Web of Science ®Google Scholar
• Deppermann KM. Influence of age and comorbidities on the chemotherapeutic management of lung cancer. Lung Cancer. 2001;33(Suppl 1):S115–120.
   Google Scholar
• Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8–32.
   PubMed Web of Science ®Google Scholar
• Baker SD, Grochow LB. Pharmacology of cancer chemotherapy in the older person. Clin Geriatr Med. 1997;13(1):169–183.
   PubMed Web of Science ®Google Scholar
• Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941–1967.
   PubMed Web of Science ®Google Scholar
• Aapro M, Bernard-Marty C, Brain EG, et al. Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Ann Oncol. 2011;22(2):257–267.
   PubMed Web of Science ®Google Scholar
• Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29(25):3457–3465.
   PubMed Web of Science ®Google Scholar
• Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118(13):3377–3386.
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659–1672.
   PubMed Web of Science ®Google Scholar
• Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012;4:CD006243.
   PubMed Web of Science ®Google Scholar
• Dall P, Lenzen G, Göhler T, et al. Trastuzumab in the treatment of elderly patients with early breast cancer: results from an observational study in Germany. J Geriatr Oncol. 2015;6(6):462–469.
   PubMed Web of Science ®Google Scholar
• Rastogi P, Jeong J, Geyer CE, et al. Five year update of cardiac dysfunction in NSABP B-31: a randomized trial of AC→paclitaxel vs AC→paclitaxel with trastuzumab in HER2-positive, node-positive, operable breast cancer [abstract LBA513]. Proc Am Soc Clin Oncol. 2007;25.
   Google Scholar
• Chen J, Long JB, Hurria A, et al. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol. 2012;60(24):2504–2512.
   PubMed Web of Science ®Google Scholar
• Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273–1283.
   PubMed Web of Science ®Google Scholar
• Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015;372(2):134–141.
   PubMed Web of Science ®Google Scholar
• Pierga J-Y, Girre V, Laurence V, et al. Characteristics and outcome of 1755 operable breast cancers in women over 70 years of age. Breast. 2004;13(5):369–375.
   PubMed Web of Science ®Google Scholar
• Laird-Fick HS, Gardiner JC, Tokala H, et al. HER2 status in elderly women with breast cancer. J Geriatr Oncol. 2013;4(4):362–367.
   PubMed Web of Science ®Google Scholar
• Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst. 2000;92(7):550–556.
   PubMed Web of Science ®Google Scholar
• Vetter M, Huang DJ, Bosshard G, et al. Breast cancer in women 80 years of age and older: a comprehensive analysis of an underreported entity. Acta Oncol. 2013;52(1):57–65.
   PubMed Web of Science ®Google Scholar
• Schonberg MA, Marcantonio ER, Li D, et al. Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival. J Clin Oncol. 2010;28(12):2038–2045.
   PubMed Web of Science ®Google Scholar
• Le Saux O, Ripamonti B, Bruyas A, et al. Optimal management of breast cancer in the elderly patient: current perspectives. Clin Interv Aging. 2015;10:157–174.
   PubMed Web of Science ®Google Scholar
• Dowsett M, Forbes JF, Bradley R, et al. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341–1352.
   PubMed Web of Science ®Google Scholar
• Tan A, Kuo YF, Goodwin JS. Predicting life expectancy for community-dwelling older adults from Medicare claims data. Am J Epidemiol. 2013;178(6):974–983.
   PubMed Web of Science ®Google Scholar
• Henderson R, Keiding N. Individual survival time prediction using statistical models. J Med Ethics. 2005;31(12):703–706.
   PubMed Web of Science ®Google Scholar
• Fornander T, Rutqvist LE, Cedermark B, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet. 1989;1(8630):117–120.
   PubMed Web of Science ®Google Scholar
• Amir E, Seruga B, Niraula S, et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011;103(17):1299–1309.
   PubMed Web of Science ®Google Scholar
• Bushnell CD, Goldstein LB. Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis. Neurology. 2004;63(7):1230–1233.
   PubMed Web of Science ®Google Scholar
• Mann BS, Johnson JR, Kelly R, et al. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen. Clin Cancer Res. 2005;11(16):5671–5677.
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349(19):1793–1802.
   PubMed Web of Science ®Google Scholar
• Becker T, Lipscombe L, Narod S, et al. Systematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancer. J Am Geriatr Soc. 2012;60(9):1761–1767.
   PubMed Web of Science ®Google Scholar
• Khan QJ, O’Dea AP, Sharma P. Musculoskeletal adverse events associated with adjuvant aromatase inhibitors. J Oncol. 2010;2010:654348.
   Google Scholar
• Muss HB, Tu D, Ingle JN, et al. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol. 2008;26(12):1956–1964.
   PubMed Web of Science ®Google Scholar
• Lemieux J, Goss PE, Parulekar WR, et al. Patient-reported outcomes from MA.17R: a randomized of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. J Clin Oncol. 2016;34(suppl; abstr LB506).
   Google Scholar
• Ganz PA, Petersen L, Bower JE, et al. Impact of adjuvant endocrine therapy on quality of life and symptoms: observational data over 12 months from the mind-body study. J Clin Oncol. 2016;34(8):816–824.
   PubMed Web of Science ®Google Scholar
• Zwart W, Terra H, Linn SC, et al. Cognitive effects of endocrine therapy for breast cancer: keep calm and carry on? Nat Rev Clin Oncol. 2015;12(10):597–606.
   PubMed Web of Science ®Google Scholar
• Mandelblatt JS, Stern RA, Luta G, et al. Cognitive impairment in older patients with breast cancer before systemic therapy: is there an interaction between cancer and comorbidity? J Clin Oncol. 2014;32(18):1909–1918.
   PubMed Web of Science ®Google Scholar
• Phillips KA, Ribi K, Sun Z, et al. Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. Breast. 2010;19(5):388–395.
   PubMed Web of Science ®Google Scholar
• Schilder CM, Seynaeve C, Beex LV, et al. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol. 2010;28(8):1294–1300.
   PubMed Web of Science ®Google Scholar
• Jenkins V, Shilling V, Fallowfield L, et al. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology. 2004;13(1):61–66.
   PubMed Web of Science ®Google Scholar
• Crivellari D, Sun Z, Coates AS, et al. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol. 2008;26(12):1972–1979.
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Kim J, Haque R. Adherence to endocrine therapy in breast cancer adjuvant and prevention settings. Cancer Prev Res (Phila). 2014;7(4):378–387.
   PubMed Web of Science ®Google Scholar
• Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010;28(27):4120–4128.
   PubMed Web of Science ®Google Scholar
• Kahn KL, Schneider EC, Malin JL, et al. Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care. 2007;45(5):431–439.
   PubMed Web of Science ®Google Scholar
• Owusu C, Buist DS, Field TS, et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2008;26(4):549–555.
   PubMed Web of Science ®Google Scholar
• Fink AK, Gurwitz J, Rakowski W, et al. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor–positive breast cancer. J Clin Oncol. 2004;22(16):3309–3315.
   PubMed Web of Science ®Google Scholar
• Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol. 2001;19(2):322–328.
   PubMed Web of Science ®Google Scholar
• Lash TL, Fox MP, Westrup JL, et al. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat. 2006;99(2):215–220.
   PubMed Web of Science ®Google Scholar
• Kimmick G, Anderson R, Camacho F, et al. Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol. 2009;27(21):3445–3451.
   PubMed Web of Science ®Google Scholar
• Cluze C, Rey D, Huiart L, et al. Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Ann Oncol. 2012;23(4):882–890.
   PubMed Web of Science ®Google Scholar
• Riley GF, Warren JL, Harlan LC, et al. Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D. Medicare Medicaid Res Rev. 2011;1:4.
   Google Scholar
• Liu Y, Malin JL, Diamant AL, et al. Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication. Breast Cancer Res Treat. 2013;137(3):829–836.
   PubMed Web of Science ®Google Scholar
• Güth U, Myrick ME, Kandler C, et al. The use of adjuvant endocrine breast cancer therapy in the oldest old. Breast. 2013;22(5):863–868.
   PubMed Web of Science ®Google Scholar
• Coleman R, Powles T, Paterson A, et al. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015;386(10001):1353–1361.
   PubMed Web of Science ®Google Scholar
• Sawaki M, Tokudome N, Mizuno T, et al. Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)]. Jpn J Clin Oncol. 2011;41(5):709–712.
   PubMed Web of Science ®Google Scholar